Best Ways to Quantify Brain Health for Research Advancements

September 14, 2021Henry Peck

Research surrounding brain health and neurological disease is increasing rapidly, yet many research studies are still utilizing old-school pencil and paper legacy tests or digitized versions of such assessments. Two major areas of research requiring robust methods for measuring and monitoring brain health include:

  1. Studies assessing brain health as a dependent variable of a therapy or intervention.
  2. Studies assessing patterns and correlations in brain health over time to inform drug development.

Many of these studies require highly granular data, diverse data streams, and/or large quantities of data to confirm hypotheses or detect new traits or patterns associated with a particular neurological disease. Meeting these intensive requirements for data acquisition is particularly challenging when utilizing traditional neurocognitive assessment tools to quantify brain health for research advancements. Research shows that portable technologies for monitoring brain health—such as sensors, wearables, and mobile devices—may provide new and valuable insights to research studies and clinical trials due to the rich, large quantities of data that can be collected.

Below, we detail the limitations of traditional neurocognitive assessment tools for research applications and explore requirements for quantifying brain health for research advancements within each of the two research categories listed above.

Limitations of Traditional Cognitive Assessment Tools Used for Research Applications 

Conventional neurocognitive assessment tools, such as the Mini-Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), and Mini-Cog, are commonly used for neurocognitive function screening and are often used for research purposes. While these assessments are good indicators of overall cognitive function, the very nature of these assessments poses challenges to research and clinical trial applications. 

Limitations include the following:

  1. The MMSE, MoCA, and Mini-Cog depend strongly on specific, symptom-oriented testing that does not provide the level of data granularity and specificity required to carry out a complete, unbiased story in clinical trials and research studies. 
  2. Traditional neurocognitive assessments lack the infrastructure to perform longitudinal studies of brain health and studies that require large quantities of data.
  3. The MMSE, MoCA, and Mini-Cog depend on a human to administer the tests and interpret the results, meaning they cannot be done in a remote setting and they introduce the risk of bias or human-to-human variability.
  4. These assessments lack a detailed scoring system and measurement scale and are not sensitive to intra-individual change. Thus, they may not provide the level of insight into brain function required for specific research applications.

Many studies and clinical trials have moved away from pencil and paper tests and towards digitized versions, such as BrainCheck, Savonix, Cogstate, and Cantab Mobile. While digitized versions provide a means for remote brain health monitoring, they retain many of the above limitations. 

Requirements for Measuring Brain Health for Research Advancements

Every research study and clinical trial will have unique requirements for measuring and analyzing brain health. However, there are common characteristics to look for in a brain health assessment tool for specific research areas, such as those assessing brain health as a dependent variable and those tracking brain health within a population to inform drug development. 

Assessing Neurocognitive Function as a Dependent Variable

When performing studies that analyze brain health as a dependent variable while altering independent variables, such as sleep, diet, and exercise, tools that produce extremely granular data are crucial. For such studies, tools must be sensitive to intra-individual changes in brain health, as these small changes in neurocognitive function may be indicative of the efficacy of the given independent variable. As these types of studies typically take place over a significant period of time, they may require a brain health assessment tool that allows subjects to be monitored remotely. Finally, it is important to produce easily reportable data that researchers can view, digest, and report on in an organized and systematic manner.

Research in Drug Development and Discovery

Research studies that aim to identify new traits, patterns, correlations, and biomarkers associated with a particular neurological disease or disorder to inform treatment options and drug development have unique challenges. Data granularity is key, but so is data quantity. Such areas of research require diverse data streams that assess a wide range of cognitive and functional abilities across many neurocognitive domains.

Developing a Robust Method for Brain Health Assessment and Monitoring

Altoida is developing a Precision Neurology platform to measure and analyze nearly 800 digital biomarkers shown to be clinically significant through over 20 years of research. Users complete a set of hyper-realistic augmented reality activities that are designed to place the brain under a neurocognitive load representative of complex activities of daily living using just a smartphone or tablet. Altoida’s app-based device will provide robust measurements of cognitive and functional brain health to produce highly granular data. These digital biomarkers map to 13 unique neurocognitive domains that will be used to measure and monitor neurocognitive function over time.

Altoida’s web-based platform will allow clinical stakeholders and researchers to manage and monitor subjects. Patient data such as current prescriptions, general health information, and results from Altoida’s device will be available in the platform and can be monitored over time to reveal trends and patterns while flagging areas of concern.

To learn more about how Altoida’s Precision Neurology device and platform can be used to quantify brain health for research advancements, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021